Takeda Pharmaceutical has been granted a patent for a heterocyclic compound that acts as an orexin type 2 receptor agonist. This compound is intended for the prophylaxis or treatment of narcolepsy, potentially offering new therapeutic options for this sleep disorder. GlobalData’s report on Takeda Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takeda Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Takeda Pharmaceutical's grant share as of July 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12071434B2 outlines a series of claims related to a novel compound characterized by a specific chemical formula. The claims detail various structural components of the compound, including substituents such as methylene groups, oxygen atoms, and various alkyl and cycloalkyl groups. Notably, the compound can exist in different forms, including salts, and features specific groups like sulfonyl and carbonyl, which may be halogenated or substituted. The patent also identifies particular examples of the compound, including N-[(5R,6S)-5-[(2-Fluoro[1,1'-biphenyl]-3-yl)methyl]-4-oxo-3-(propan-2-yl)-3,4,5,6,7,8-hexahydroquinazolin-6-yl]cyclopropanesulfonamide and its derivatives.
In addition to the compound's structural claims, the patent specifies its potential applications in medicine, particularly as an orexin type 2 receptor agonist. The claims suggest that the compound or its salts may be utilized in the prophylaxis or treatment of narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. Furthermore, methods for activating the orexin type 2 receptor and treating narcolepsy in mammals through the administration of the compound are also included in the claims, indicating a therapeutic pathway for addressing this condition.
To know more about GlobalData’s detailed insights on Takeda Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
